Health sciences Company
PreveCeutical Medical Inc. (CSE:PREV, OTCQB:PRVCF, Forum) released positive results from the preliminary screening of key peptides from its scorpion venom-derived peptide research and development program on Monday. The Company expects to generate therapeutics intended for applications and understand the activities of such peptides in cell-based brain cancer models.
More information can be found
here.
PreveCeutical recently appointed former
Pfizer Inc. executive
Dr. Makarand Jawadekar as Company President.
FULL DISCLOSURE: PreveCeutical Medical Inc. is a client of Stockhouse Publishing.